Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Heather A Jacene, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Hurwitz M, Buscombe JR, Jacene HA, Klitzke AK, Lamonica D, Lu Y, Pryma DA, Rohren EM, Speer TW, Subramaniam RM, Thompson HM, Tomblyn MB, Wong WW, Xiao Y, Banks KP, Brown RKJ. ACR-ACNM-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radium-223. Am J Clin Oncol. 2020 Aug; 43(8):539-544. PMID: 32520788.
    Citations:    
  2. Jacene HA, DiPiro PJ, Bellon J, Hu J, Cheng SC, Warren L, Schlosnagle E, Nakhlis F, Rosenbluth JM, Yeh E, Overmoyer B. Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning. Breast Cancer Res Treat. 2020 Jun; 181(2):383-390. PMID: 32318957.
    Citations:    
  3. Merryman RW, Edwin N, Redd R, Bsat J, Chase M, LaCasce A, Freedman A, Jacobson C, Fisher D, Ng S, Crombie J, Kim A, Odejide O, Davids MS, Brown JR, Jacene H, Cashen A, Bartlett NL, Mehta-Shah N, Ghobadi A, Kahl B, Joyce R, Armand P, Jacobsen E. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020 Mar 10; 4(5):858-867. PMID: 32126141.
    Citations:    
  4. Robertson MS, Sakellis CG, Hyun H, Jacene HA. Extraprostatic Uptake of 18F-Fluciclovine: Differentiation of Nonprostatic Neoplasms From Metastatic Prostate Cancer. AJR Am J Roentgenol. 2020 03; 214(3):641-648. PMID: 31939697.
    Citations:    
  5. Thomas R, Shinagare AB, Rosenthal MH, Lee B, Jacene HA, Johnston MA, Overmoyer BA. Computed tomographic assessment of lean body mass in patients on selective androgen receptor modulator. Clin Imaging. 2020 02; 59(2):100-103. PMID: 31812880.
    Citations:    
  6. Jacene HA. 2019 SNMMI Highlights Lecture: General Nuclear Medicine and Molecular Imaging. J Nucl Med. 2019 Oct; 60(10):13N-18N. PMID: 31575717.
    Citations:    
  7. Nakhlis F, Regan MM, Chun YS, Dominici LS, Caterson S, Bellon JR, Warren L, Yeh ED, Jacene HA, King TA, Overmoyer B. Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Dana-Farber Cancer Institute's Inflammatory Breast Cancer Program experience. Breast J. 2020 Mar; 26(3):384-390. PMID: 31448540.
    Citations:    
  8. Choi HJ, Jacene H, Kim CK. No delayed imaging or CCK administration is needed in most cases when bowel excretion does not occur but gallbladder fills promptly. Ann Nucl Med. 2019 Oct; 33(10):740-745. PMID: 31297700.
    Citations:    
  9. Morris MJ, Loriot Y, Sweeney CJ, Fizazi K, Ryan CJ, Shevrin DH, Antonarakis ES, Pandit-Taskar N, Deandreis D, Jacene HA, Vesselle H, Petrenciuc O, Lu C, Carrasquillo JA, Higano CS. Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. Eur J Cancer. 2019 06; 114:107-116. PMID: 31082669.
    Citations:    
  10. Ng TSC, Sakellis CG, Jacene HA. Extraosseous Colonic Uptake of 99mTc-MDP Associated With Iodinated Contrast CT. Clin Nucl Med. 2019 May; 44(5):414-416. PMID: 30829870.
    Citations:    
  11. Shah S, Luke JJ, Jacene HA, Chen T, Giobbie-Hurder A, Ibrahim N, Buchbinder EL, McDermott DF, Flaherty KT, Sullivan RJ, Lawrence DP, Ott PA, Hodi FS. Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. Melanoma Res. 2018 12; 28(6):605-610. PMID: 30211813.
    Citations:    Fields:    
  12. Jacene HA, Youn T, DiPiro PJ, Hu J, Cheng SC, Franchetti Y, Shah H, Bellon JR, Warren L, Schlosnagle E, Nakhlis F, Rosenbluth J, Yeh E, Overmoyer B. Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade. Clin Breast Cancer. 2019 04; 19(2):146-155. PMID: 30584057.
    Citations:    Fields:    
  13. Jacene HA. 2018 SNMMI Highlights Lecture: General Nuclear Medicine. J Nucl Med. 2018 Oct; 59(10):7N-13N. PMID: 30275291.
    Citations:    Fields:    
  14. Abbott A, Sakellis CG, Andersen E, Kuzuhara Y, Gilbert L, Boyle K, Kulke MH, Chan JA, Jacene HA, Van den Abbeele AD. Guidance on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division. J Nucl Med Technol. 2018 Sep; 46(3):237-244. PMID: 30076245.
    Citations:    Fields:    Translation:Humans
  15. Abbott A, Jacene H. 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy. J Nucl Med Technol. 2018 Sep; 46(3):245-246. PMID: 30076242.
    Citations:    Fields:    
  16. McKay RR, Bossé D, Gray KP, Michaelson MD, Krajewski K, Jacene HA, Walsh M, Bellmunt J, Pomerantz M, Harshman LC, Choueiri TK. Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. Clin Cancer Res. 2018 09 01; 24(17):4081-4088. PMID: 29848570.
    Citations:    Fields:    
  17. Rosica D, Cheng SC, Hudson M, Sakellis C, Van den Abbeele AD, Kim CK, Jacene HA. Effects of hyperglycemia on fluorine-18-fluorodeoxyglucose biodistribution in a large oncology clinical practice. Nucl Med Commun. 2018 May; 39(5):417-422. PMID: 29629997.
    Citations:    Fields:    Translation:Humans
  18. Jacene H, Gomella L, Yu EY, Rohren EM. Hematologic Toxicity From Radium-223 Therapy for Bone Metastases in Castration-Resistant Prostate Cancer: Risk Factors and Practical Considerations. Clin Genitourin Cancer. 2018 08; 16(4):e919-e926. PMID: 29678471.
    Citations:    Fields:    
  19. Karls S, Shah H, Jacene H. PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up. Semin Nucl Med. 2018 01; 48(1):37-49. PMID: 29195616.
    Citations: 1     Fields:    Translation:Humans
  20. Kamran SC, Jacene HA, Chen YH, Mauch PM, Ng AK. Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD?×?two cycles followed by FDG-PET/CT restaging and 20?Gy of involved-site radiotherapy. Leuk Lymphoma. 2018 06; 59(6):1384-1390. PMID: 28937297.
    Citations:    Fields:    Translation:Humans
  21. Alabed YZ, Cheng SC, Mudge C, Sakellis C, Van den Abbeele AD, Campos SM, Jacene HA. Surveillance Imaging in Patients With Endometrial Cancer in First Remission. Curr Probl Diagn Radiol. 2018 Sep; 47(5):311-316. PMID: 28917433.
    Citations:    Fields:    Translation:HumansPHPublic Health
  22. Jacene H, Crandall J, Kasamon YL, Ambinder RF, Piantadosi S, Serena D, Kasecamp W, Wahl RL. Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma. Mol Imaging Biol. 2017 06; 19(3):429-436. PMID: 27798787.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  23. Nakhlis F, Regan MM, Warren LE, Bellon JR, Hirshfield-Bartek J, Duggan MM, Dominici LS, Golshan M, Jacene HA, Yeh ED, Mullaney EE, Overmoyer B. The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer. Ann Surg Oncol. 2017 Sep; 24(9):2563-2569. PMID: 28560598.
    Citations:    Fields:    Translation:Humans
  24. O JH, Jacene H, Luber B, Wang H, Huynh MH, Leal JP, Wahl RL. Quantitation of Cancer Treatment Response by 18F-FDG PET/CT: Multicenter Assessment of Measurement Variability. J Nucl Med. 2017 09; 58(9):1429-1434. PMID: 28360211.
    Citations:    
  25. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 01 12; 376(2):125-135. PMID: 28076709.
    Citations: 104     Fields:    Translation:HumansCTClinical Trials
  26. Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, Hoos A, Barrington SF, Armand P. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016 11 24; 128(21):2489-2496. PMID: 27574190.
    Citations: 25     Fields:    Translation:Humans
  27. McKay RR, Jacobus S, Fiorillo M, Ledet EM, Cotogna PM, Steinberger AE, Jacene HA, Sartor O, Taplin ME. Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy. Clin Genitourin Cancer. 2017 04; 15(2):e289-e298. PMID: 27651103.
    Citations: 2     Fields:    Translation:Humans
  28. Van den Abbeele AD, Krajewski KM, Tirumani SH, Fennessy FM, DiPiro PJ, Nguyen QD, Harris GJ, Jacene HA, Lefever G, Ramaiya NH. Cancer Imaging at the Crossroads of Precision Medicine: Perspective From an Academic Imaging Department in a Comprehensive Cancer Center. J Am Coll Radiol. 2016 Apr; 13(4):365-71. PMID: 26774886.
    Citations: 1     Fields:    Translation:Humans
  29. Tirumani SH, Sakellis C, Jacene H, Shinagare AB, Munshi NC, Ramaiya NH, Van den Abbeele AD. Role of FDG-PET/CT in Extramedullary Multiple Myeloma: Correlation of FDG-PET/CT Findings With Clinical Outcome. Clin Nucl Med. 2016 Jan; 41(1):e7-13. PMID: 26252323.
    Citations: 1     Fields:    Translation:Humans
  30. Mingos M, Howard S, Giacalone N, Kozono D, Jacene H. Systemic Immune Response to Vaccination on FDG-PET/CT. Nucl Med Mol Imaging. 2016 Dec; 50(4):358-361. PMID: 27994693.
    Citations: 1     
  31. Mandelker D, Dal Cin P, Jacene HA, Armand P, Stone RM, Lindeman NI. Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing. Exp Hematol Oncol. 2015; 4:30. PMID: 26457233.
    Citations: 1     
  32. Warren LE, Guo H, Regan MM, Nakhlis F, Yeh ED, Jacene HA, Hirshfield-Bartek J, Overmoyer BA, Bellon JR. Inflammatory breast cancer and development of brain metastases: risk factors and outcomes. Breast Cancer Res Treat. 2015 May; 151(1):225-32. PMID: 25893587.
    Citations: 3     Fields:    Translation:Humans
  33. Warren LE, Guo H, Regan MM, Nakhlis F, Yeh ED, Jacene HA, Hirshfield-Bartek J, Overmoyer BA, Bellon JR. Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management. Ann Surg Oncol. 2015 Aug; 22(8):2483-91. PMID: 25791789.
    Citations: 2     Fields:    Translation:Humans
  34. Kwak JJ, Tirumani SH, Van den Abbeele AD, Koo PJ, Jacene HA. Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics. 2015 Mar-Apr; 35(2):424-37. PMID: 25763727.
    Citations: 11     Fields:    Translation:Humans
  35. Tirumani SH, LaCasce AS, Jacene HA. Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma. PET Clin. 2015 Apr; 10(2):207-25. PMID: 25829087.
    Citations: 4     Fields:    Translation:Humans
  36. Abi-Ghanem AS, McGrath MA, Jacene HA. Radionuclide therapy for osseous metastases in prostate cancer. Semin Nucl Med. 2015 Jan; 45(1):66-80. PMID: 25475380.
    Citations: 2     Fields:    Translation:HumansAnimals
  37. Saboo SS, Ramaiya N, Jacene H, Rainville I, Diller L, Hornick JL, George S. Synchronous small bowel and atypical primary leiomyosarcoma of inferior vena cava in a patient with RB1 mutation. Abdom Imaging. 2014 Feb; 39(1):33-9. PMID: 22581272.
    Citations: 1     Fields:    Translation:Humans
  38. Grant P, Sakellis C, Jacene HA. Gynecologic oncologic imaging with PET/CT. Semin Nucl Med. 2014; 44(6):461-78. PMID: 25362236.
    Citations: 5     Fields:    Translation:Humans
  39. Domachevsky L, Jacene HA, Sakellis CG, Kim CK. Postradiation changes in tissues: evaluation by imaging studies with emphasis on fluorodeoxyglucose-PET/computed tomography and correlation with histopathologic findings. PET Clin. 2014 Apr; 9(2):217-35. PMID: 25030284.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  40. Yeh ED, Jacene HA, Bellon JR, Nakhlis F, Birdwell RL, Georgian-Smith D, Giess CS, Hirshfield-Bartek J, Overmoyer B, Van den Abbeele AD. What radiologists need to know about diagnosis and treatment of inflammatory breast cancer: a multidisciplinary approach. Radiographics. 2013 Nov-Dec; 33(7):2003-17. PMID: 24224593.
    Citations: 3     Fields:    Translation:Humans
  41. Tirumani SH, Jagannathan JP, Krajewski KM, Shinagare AB, Jacene H, Ramaiya NH. Imatinib and beyond in gastrointestinal stromal tumors: A radiologist's perspective. AJR Am J Roentgenol. 2013 Oct; 201(4):801-10. PMID: 24059369.
    Citations: 7     Fields:    Translation:Humans
  42. Pyo J, Won Kim K, Jacene HA, Sakellis CG, Brown JR, Van den Abbeele AD. End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis. Clin Cancer Res. 2013 Dec 01; 19(23):6566-77. PMID: 24052020.
    Citations: 1     Fields:    Translation:Humans
  43. Hawryluk EB, O'Regan KN, Sheehy N, Guo Y, Dorosario A, Sakellis CG, Jacene HA, Wang LC. Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: a study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women's Cancer Center. J Am Acad Dermatol. 2013 Apr; 68(4):592-599. PMID: 23127473.
    Citations: 13     Fields:    Translation:Humans
  44. Zukotynski K, Lewis A, O'Regan K, Jacene H, Sakellis C, Almodovar S, Israel D. PET/CT and renal pathology: a blind spot for radiologists? Part 2--lymphoma, leukemia, and metastatic disease. AJR Am J Roentgenol. 2012 Aug; 199(2):W168-74. PMID: 22826418.
    Citations: 4     Fields:    Translation:Humans
  45. Zukotynski K, Lewis A, O'Regan K, Jacene H, Sakellis C, Krajewski K, Israel D. PET/CT and renal pathology: a blind spot for radiologists? Part 1, primary pathology. AJR Am J Roentgenol. 2012 Aug; 199(2):W163-7. PMID: 22826417.
    Citations: 4     Fields:    Translation:Humans
  46. Halasz LM, Jacene HA, Catalano PJ, Van den Abbeele AD, Lacasce A, Mauch PM, Ng AK. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):e647-54. PMID: 22607911.
    Citations: 4     Fields:    Translation:Humans
  47. Graham MM, Jacene HA. Molecular imaging training for nuclear medicine residents. J Nucl Med. 2012 Apr; 53(4):655-7. PMID: 22410460.
    Citations: 1     Fields:    Translation:Humans
  48. Kasamon YL, Jacene HA, Gocke CD, Swinnen LJ, Gladstone DE, Perkins B, Link BK, Popplewell LL, Habermann TM, Herman JM, Matsui WH, Jones RJ, Ambinder RF. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood. 2012 May 03; 119(18):4129-32. PMID: 22343727.
    Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
  49. Jacene H. Molecular imaging training course debuts. J Nucl Med. 2012 Jan; 53(1):16NA. PMID: 22213830.
    Citations:    Fields:    
  50. Jacene HA, Cohade CC, Zhang Z, Wahl RL. The relationship between patients' serum glucose levels and metabolically active brown adipose tissue detected by PET/CT. Mol Imaging Biol. 2011 Dec; 13(6):1278-83. PMID: 21140233.
    Citations: 12     Fields:    Translation:Humans
  51. Kasamon YL, Jacene HA, Swinnen LJ, Popplewell L, Link BK, Habermann TM, Herman JM, Jones RJ, Ambinder RF. Multicenter phase II study of rituximab-ABVD in classic Hodgkin lymphoma (cHL). J Clin Oncol. 2011 May 20; 29(15_suppl):8039. PMID: 28023574.
    Citations:    
  52. Baechler S, Hobbs RF, Jacene HA, Bochud FO, Wahl RL, Sgouros G. Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab. J Nucl Med. 2010 Dec; 51(12):1878-84. PMID: 21098795.
    Citations: 6     Fields:    Translation:HumansCells
  53. Messersmith WA, Jimeno A, Jacene H, Zhao M, Kulesza P, Laheru DA, Kahn Y, Spira A, Dancey J, Iacobuzio-Donahue C, Donehower RC, Carducci M, Rudek MA, Hidalgo M. Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Clin Colorectal Cancer. 2010 Dec; 9(5):297-304. PMID: 21208844.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  54. Goudarzi B, Jacene HA, Wahl RL. Measuring the "unmeasurable": assessment of bone marrow response to therapy using FDG-PET in patients with lymphoma. Acad Radiol. 2010 Sep; 17(9):1175-85. PMID: 20634105.
    Citations: 1     Fields:    Translation:Humans
  55. Chien D, Jacene H. Imaging of parathyroid glands. Otolaryngol Clin North Am. 2010 Apr; 43(2):399-415, x. PMID: 20510723.
    Citations: 1     Fields:    Translation:Humans
  56. Hobbs RF, Baechler S, Wahl RL, He B, Song H, Esaias CE, Frey EC, Jacene H, Sgouros G. Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy. J Nucl Med. 2010 Mar; 51(3):368-75. PMID: 20150265.
    Citations: 7     Fields:    Translation:Humans
  57. Baba S, Jacene HA, Engles JM, Honda H, Wahl RL. CT Hounsfield units of brown adipose tissue increase with activation: preclinical and clinical studies. J Nucl Med. 2010 Feb; 51(2):246-50. PMID: 20124047.
    Citations: 54     Fields:    Translation:HumansAnimals
  58. Jacene HA, Ginsburg P, Kwon J, Nguyen GC, Montgomery EA, Bayless TM, Wahl RL. Prediction of the need for surgical intervention in obstructive Crohn's disease by 18F-FDG PET/CT. J Nucl Med. 2009 Nov; 50(11):1751-9. PMID: 19837758.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  59. Jacene HA, Leboulleux S, Baba S, Chatzifotiadis D, Goudarzi B, Teytelbaum O, Horton KM, Kamel I, Macura KJ, Tsai HL, Kowalski J, Wahl RL. Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy. J Nucl Med. 2009 Nov; 50(11):1760-9. PMID: 19837757.
    Citations: 23     Fields:    Translation:Humans
  60. Lyford-Pike S, Ha PK, Jacene HA, Saunders JR, Tufano RP. Limitations of PET/CT in determining need for neck dissection after primary chemoradiation for advanced head and neck squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec. 2009; 71(5):251-6. PMID: 19776658.
    Citations: 3     Fields:    Translation:Humans
  61. Jacene HA, Wahl RL. The importance of brown adipose tissue. N Engl J Med. 2009 Jul 23; 361(4):417-8; author reply 419-20. PMID: 19630142.
    Citations: 2     Fields:    Translation:Humans
  62. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009 May; 50 Suppl 1:122S-50S. PMID: 19403881.
    Citations: 702     Fields:    Translation:Humans
  63. He B, Wahl RL, Sgouros G, Du Y, Jacene H, Kasecamp WR, Flinn I, Hammes RJ, Bianco J, Kahl B, Frey EC. Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--patient studies. Med Phys. 2009 May; 36(5):1595-601. PMID: 19544775.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  64. Ma WW, Jacene H, Song D, Vilardell F, Messersmith WA, Laheru D, Wahl R, Endres C, Jimeno A, Pomper MG, Hidalgo M. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol. 2009 Jun 01; 27(16):2697-704. PMID: 19380450.
    Citations: 48     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
  65. He B, Du Y, Segars WP, Wahl RL, Sgouros G, Jacene H, Frey EC. Evaluation of quantitative imaging methods for organ activity and residence time estimation using a population of phantoms having realistic variations in anatomy and uptake. Med Phys. 2009 Feb; 36(2):612-9. PMID: 19292001.
    Citations: 16     Fields:    Translation:HumansCells
  66. Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, Jacene HA, Ewertz ME, Bournaud C, Wahl RL, Sherman SI, Ladenson PW, Schlumberger M. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab. 2009 Apr; 94(4):1310-6. PMID: 19158200.
    Citations: 18     Fields:    Translation:Humans
  67. Jacene HA, Filice R, Kasecamp W, Wahl RL. 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. J Nucl Med. 2009 Jan; 50(1):8-17. PMID: 19091903.
    Citations: 9     Fields:    Translation:Humans
  68. Bonekamp D, Jacene H, Bartelt D, Aygun N. Conversion of FDG PET activity of fibrous dysplasia of the skull late in life mimicking metastatic disease. Clin Nucl Med. 2008 Dec; 33(12):909-11. PMID: 19033807.
    Citations: 6     Fields:    Translation:HumansCells
  69. Brenner ME, Jacene HA. Recurrent or residual hyperparathyroidism and thyroid cancer effectively evaluated with scintigraphy. Otolaryngol Clin North Am. 2008 Dec; 41(6):1117-33, viii-ix. PMID: 19040973.
    Citations: 1     Fields:    Translation:Humans
  70. Lodge MA, Jacene HA, Pili R, Wahl RL. Reproducibility of tumor blood flow quantification with 15O-water PET. J Nucl Med. 2008 Oct; 49(10):1620-7. PMID: 18832120.
    Citations: 5     Fields:    Translation:Humans
  71. Goudarzi B, Jacene HA, Wahl RL. Diagnosis and differentiation of bronchioloalveolar carcinoma from adenocarcinoma with bronchioloalveolar components with metabolic and anatomic characteristics using PET/CT. J Nucl Med. 2008 Oct; 49(10):1585-92. PMID: 18794276.
    Citations: 4     Fields:    Translation:Humans
  72. Jimeno A, Rudek MA, Kulesza P, Ma WW, Wheelhouse J, Howard A, Khan Y, Zhao M, Jacene H, Messersmith WA, Laheru D, Donehower RC, Garrett-Mayer E, Baker SD, Hidalgo M. Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol. 2008 Sep 01; 26(25):4172-9. PMID: 18757332.
    Citations: 26     Fields:    Translation:HumansCellsCTClinical Trials
  73. Swinnen LJ, Flinn IW, Kahl BS, Frey E, Rogers K, Jung M, Jacene H, Wahl RL. Phase I trial of yttrium 90 ibritumomab tiuxetan (90Y-RIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). J Clin Oncol. 2008 May 20; 26(15_suppl):8565. PMID: 27951111.
    Citations:    
  74. He B, Wahl RL, Du Y, Sgouros G, Jacene H, Flinn I, Frey EC. Comparison of residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--Monte Carlo simulation studies. IEEE Trans Med Imaging. 2008 Apr; 27(4):521-30. PMID: 18390348.
    Citations: 16     Fields:    Translation:Humans
  75. Mosley C, Jacene HA, Holz A, Grand DJ, Wahl RL. Extramedullary hematopoiesis on F-18 FDG PET/CT in a patient with metastatic colon carcinoma. Clin Nucl Med. 2007 Nov; 32(11):878-80. PMID: 18075428.
    Citations: 2     Fields:    Translation:Humans
  76. Jacene HA, Filice R, Kasecamp W, Wahl RL. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med. 2007 Nov; 48(11):1767-76. PMID: 17942813.
    Citations: 21     Fields:    Translation:Humans
  77. Jacene HA, Goudarzi B, Wahl RL. Scalene muscle uptake: a potential pitfall in head and neck PET/CT. Eur J Nucl Med Mol Imaging. 2008 Jan; 35(1):89-94. PMID: 17909795.
    Citations: 2     Fields:    Translation:Humans
  78. Melton GB, Lavely WC, Jacene HA, Schulick RD, Choti MA, Wahl RL, Gearhart SL. Efficacy of preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography for assessing primary rectal cancer response to neoadjuvant therapy. J Gastrointest Surg. 2007 Aug; 11(8):961-9; discussion 969. PMID: 17541799.
    Citations: 19     Fields:    Translation:Humans
  79. Lucas RG, Jacene H, Harolds J, Barnes L, Maurer A. Nuclear medicine training for radiology residents: needs assessment survey. Acad Radiol. 2007 Mar; 14(3):301-5. PMID: 17307662.
    Citations:    Fields:    
  80. Jacene HA, Stearns V, Wahl RL. Lymphadenopathy resulting from acute hepatitis C infection mimicking metastatic breast carcinoma on FDG PET/CT. Clin Nucl Med. 2006 Jul; 31(7):379-81. PMID: 16785802.
    Citations: 6     Fields:    Translation:Humans
  81. Jacene HA, Ishimori T, Engles JM, Leboulleux S, Stearns V, Wahl RL. Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies. J Nucl Med. 2006 Jun; 47(6):950-6. PMID: 16741304.
    Citations: 10     Fields:    Translation:HumansAnimals
  82. Ha PK, Hdeib A, Goldenberg D, Jacene H, Patel P, Koch W, Califano J, Cummings CW, Flint PW, Wahl R, Tufano RP. The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2006 Jan; 132(1):12-6. PMID: 16415423.
    Citations: 16     Fields:    Translation:Humans
  83. Díaz-Montes TP, Jacene HA, Wahl RL, Bristow RE. Combined FDG-positron emission tomography and computed tomography for the detection of ovarian cancer recurrence in an inguinal hernia sac. Gynecol Oncol. 2005 Sep; 98(3):510-2. PMID: 15992914.
    Citations: 2     Fields:    Translation:Humans
  84. Subhas N, Patel PV, Pannu HK, Jacene HA, Fishman EK, Wahl RL. Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET. Radiographics. 2005 Jul-Aug; 25(4):1031-43. PMID: 16009822.
    Citations: 9     Fields:    Translation:Humans
  85. Jacene HA, Cohade C, Wahl RL. F-18 FDG PET/CT in acute respiratory distress syndrome: a case report. Clin Nucl Med. 2004 Dec; 29(12):786-8. PMID: 15545878.
    Citations: 5     Fields:    Translation:Humans
  86. Jacene HA, Patel PP, Chin BB. 2-Deoxy-2-[18F] fluoro-D-glucose uptake in intercostal respiratory muscles on positron emission tomography/computed tomography: smokers versus nonsmokers. Mol Imaging Biol. 2004 Nov-Dec; 6(6):405-10. PMID: 15564151.
    Citations: 3     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Jacene's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (331)
Explore
_
Co-Authors (62)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.